Recommended Dosaging of IVERMECTIN (15mg capsule) in the Treatment of COVID-19 for Adults:

1. For general prevention:

   **One (1) capsule as a single dose. May be repeated every 3 weeks.**

   This single dose confers protection for a period of 3 weeks. This dosage is for people who are not categorized as a contact, not a probable, and not a suspect patient. They do not have any symptoms associated with COVID-19 such as fever, cough, difficulty of breathing, colds, soreness of throat, loss of smell, loss of taste, headache, body pains, weakness or any flu-like symptoms.

2. For asymptomatic contact, probable, or suspect (persons under investigation – PUI):

   **One (1) capsule every 7 days. Maximum of 3 weeks.**

   This includes patients who have undergone swab tests (RT-PCR tests) and are waiting for results. They have not manifested any symptoms associated with COVID-19.

3. For symptomatic patients who are contact, probable, or suspect (persons under monitoring – PUM), have undergone swab tests (RT-PCR tests) and are waiting for the results:

   **One (1) capsule every 3 to 7 days depending on severity of symptoms. Maximum of 4 weeks.**

4. For symptomatic patients who are tested and are confirmed positive of COVID-19 by swab tests (RT-PCR):

   **One (1) capsule every 3 to 7 days depending on severity of symptoms. Maximum of 4 weeks.**

5. For asymptomatic patients who are tested and are confirmed positive of COVID-19 by swab tests (RT-PCR):

   **One (1) capsule every 7 days. Maximum of 4 weeks.**

6. For patients who are tested and are confirmed positive for IgM or IgG (rapid blood tests) who have always been asymptomatic, or have had symptoms but are now asymptomatic:

   **No need to take Ivermectin.**

   These patients have developed a degree of immunity against the virus (SARS CoV-2).

7. For patients who are persistently positive on swab tests (RT-PCR tests) and have mild or no symptoms:

   **One (1) capsule every 3 weeks until swab tests become negative and until patient is symptom-free.**

   These patients are classified as ‘long- haulers.’ Intake of IVERMECTIN will help in eradicating their viral load.
**Noteworthy Facts:**

1. The use of IVERMECTIN in the treatment of COVID-19 is basically empirical – and based on the overwhelmingly successful experiences by numerous doctors in the treatment of their COVID-19 patients in many countries around the world. It is also observed that populations in many countries in Africa who are taking IVERMECTIN for their parasitic infections and infestations are to a certain degree protected from the COVID-19 pandemic.

2. Randomized clinical trials in the use of IVERMECTIN for the treatment of COVID-19 are presently have been completed with very successful results. IVERMECTIN was initially studied and tested in vitro for SARS CoV-2 and was found to reduce viral load by 5,000 fold in 48 hours. Notwithstanding, IVERMECTIN in past researches have been found to be effective in inactivating numerous viruses such as: Dengue 1-4, Zika, Yellow Fever, West Nile, Hendra, Newcastle, Venezuelan Equine Encephalitis, Chikungunya, Senliki, Sindbis, Avian Influenza A, and Human Immuno-deficiency Virus Type-1 among others.

3. IVERMECTIN is an FDA-approved anti-parasitic drug in the US as well as in the Philippines. Repurposing its use for the treatment of COVID-19 does not alter its safety profile and is proper as a matter of contingency considering that the dosage is the same. Modification is inherent upon the rightful judgment of the physician as they see fit according to individual needs of their patients. Just like any other approved drugs, IVERMECTIN also exhibits certain side effects and adverse reactions, although these are very rare. But just like any other drugs, overdosing can be dangerous. This drug however is categorized as ‘very safe’ when taken according to recommended dosages.

4. IVERMECTIN does not exhibit any untoward effect on any of the conditions of Metabolic Syndrome such as insulin resistance and hyperglycemia in diabetes mellitus, hypertension, dyslipidemia, obesity, fatty liver disease, hyperuricemia, cardiovascular disease, cerebrovascular disease, and cancer. Recent studies have established its safety during pregnancy. It must however be taken with precaution by pregnant and lactating women.

5. IVERMECTIN being a prescription drug requires the prescription and guidance of a physician. I am inclined to prescribing this drug as a contingent measure in the fight against COVID-19. For my patients, please address your concern directly to me.

6. Combating COVID-19 rests primarily on a good immune system. IVERMECTIN is only an adjunct to treatment. Patients are recommended to take also the following:
   a) High-dose oral Vitamin C (Sodium Ascorbate) 3,000 mg. to 10,000 mg. in divided dosages depending on the symptoms of the patient.
   b) Zinc Sulphate 20 mg once a day.

7. Patients who have advanced in COVID-19 will require high doses of intravenous Vitamin C, intravenous MgSO4 EDTA and DMSO in addition to IVERMECTIN and other supportive measures. Severe conditions necessitate hospitalization.
- Allan A. Landrito, M.D.
  (dr.allan.landrito@gmail.com)